Market Analysis - Diabetes Asia Pacific 2017
Global Market for Diabetes Therapies & Diagnostics is to be worth $51.2 billion in 2015. The diabetes market, consisting mainly of Type 1 and Type 2 diabetes, is large and growing significantly.
According to a new technical market research report, 'Diabetes Therapies and Diagnostics' from BCC Research, the global market value for diabetes therapies and diagnostics is an estimated $38 billion in 2010, but is expected to increase to $51.2 billion in 2015, for a 5-year compound annual growth rate (CAGR) of 6.1 percent. The largest segment of the market, insulin products (including administration devices), is estimated to be worth $16.4 billion in 2010 and is expected to increase at a CAGR of 6.1 per cent to reach $22 billion in 2015.
Monitoring devices and accessories, the second-largest segment, is expected to reach $14.1 billion in 2015, after increasing from the 2010 estimate of $11.3 billion at a CAGR of 4.5 per cent. The fastest-growing segment, oral hypoglycemic drugs, is projected to increase at a CAGR of 8 per cent, increasing from an estimated $10.3 billion in 2010 to $15.1 billion in 2015.
Being recognized as a world-renowned organization, Conference Series LLC takes pride to introduce the commencement of “19th Asia Pacific Diabetes Conference” from July 20-22, 2017 at Melbourne, Australia. The Annual conference aims to provide an opportunity to share knowledge, expertise along with unparalleled networking opportunities between a large number of medical and industrial professionals in this sphere.The Annual Meetings gather renowned scientists, physicians, surgeons, young researchers, industrial delegates and talented student communities in the field of diabetic medicine under a single roof where networking and global partnering happens for the acceleration of future research.Scientific Sessions include various sessions which emphasis on Diabetes Types and Symptoms, Genesis of Diabetes, Pathophysiology of diabetes , Screening of Diabetes, Technologies for the Treatment of Diabetes, Transplantations in Diabetes, Rising Focus in Diabetes Research, Hereditary of diabetes, Methodologies to insulin administration, Neuro Endocrinology, Complications in diabetes, Computerized applications in Diabetes mitigations, Management of Diabetes, Biomarker Discovery for Treatment of Diabetes.
Conference Series LLC through its Open Access Initiative is committed to making genuine and reliable contributions to the scientific community. OMICS Publishing Group hosts over 400 leading-edge peers reviewed. Open Access journals and has organized over 300 scientific conferences all over the world.
Conference series LLC welcomes all the scientists, physicians, surgeons, young researchers, industrial delegates and talented student communities in the field of diabetic medicine to attend this Diabetes Conferences, where all the aspects of diabetes will be discussed under the single roof. Diabetes Asia Pacific-2017 will be an excellent amalgamation of academia and industry as it involves every aspect of empirical and conceptual thinking in exploring new dimensions in this field. It is open to all types of research methodologies both from academia and industry.
Diabetes Asia Pacific 2017 is an international platform for presenting research about diabetes management and therapeutics, exchanging ideas about it and thus, contributes to the dissemination of knowledge in the management of the disease for the benefit of the society. Diabetes Asia Pacific 2017 is where the future of management and novel therapeutics for the disease intersects.
Diabetes has increasingly become a lifestyle-related disease as it afflicts young and old. In 2013, the value of the diabetes therapeutics market in Asia-Pacific (APAC) countries was an estimated $6.5 billion, and it is forecast to grow at a Compound Annual Growth Rate (CAGR) of 7.1% between 2013 and 2020 to $10.5 billion. The latest report states that of the four major APAC countries (China, India, Japan and Australia), China will see the fastest expansion, with a CAGR of 11.1% over the forecast period. This will be driven by an increase in the prevalent population due to urbanization, advancement in the lifestyle of the people and by expected drug launches.